BioMark and Going Global (Spring 2013)

Going Global completed two visits to China and signed a collaboration agreement with Dr. Liu and his team. The collaboration includes use of BioMark’s detection system for China’s national cancer screening program and the downstream development initiatives. Dr. Liu’s team includes lab specialist, pharmacologists, medical institute development experts and screening specialists.

BioMark and Manitoba Tumor Bank (MTB) (Spring 2013)

Manitoba Tumor Bank /BioMark initiatives continue to next phase. BioMark has received targeted biopsy samples from tumor bank and will commence quantification studies using relevant methodologies –qPRC or Quantigene. Results from those studies will be shared and presented to Manitoba Tumor Bank and Cancer Care Manitoba specialists.

BioMark at International Guangzhou Forum on Cancer (IGFC) (Spring 2013)

BioMark has been invited by 2013 International Guangzhou Forum on Cancer (IGFC) to attend and present a scientific poster. IGFC is an annual event focusing on New Cancer Therapy and Prevention sponsored by Fuda Cancer Hospital and Jinan University of Medicine, China and is tailored for a select medical audiences.

Screening Interest from Developing Countries (Spring 2013)

BioMark has received several expressions of interest from medical development group based in South Africa and the Radiation and Isotopes Center from Sudan. Recently Dr. Hussein M.A. Hamad from the Radiation and Isotopes Center based in Khartoum, Sudan, discussed avenues for potential cancer screening tests across Sudan using BioMark’s IVD kits. Dr. Hussein M.A. Hamad is a pioneer in oncology and has a private practice but maintains an effective teaching and medical training program.

Patent Portfolio Expansion (Spring 2013)

BioMark and UVic team led by Dr. Reuven and Fraser are working on a new patent for the IR Raman system. The team is establishing an exclusive licensing agreement for this application and other related areas.

Cancer Care Manitoba Gives Green Light for Clinical Trial (Spring 2013)

Patient recruitment and facility preparations are underway for BioMark’s phase III Trial. The Trial will be managed by the team from St. Boniface Research Center and the principal investigator Dr. Andrew Maskymiuk.

Funding and Roadshow (Spring 2013)

BioMark is currently in discussion with various private investors and pharmaceutical companies.

Share this post:

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
FSE: 20B

Related articles ...

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.